These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355 [TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Hagenbeek A Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741 [TBL] [Abstract][Full Text] [Related]
7. [Assessment for the image interpretation of 111In-ibritumomab tiuxetan in the phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma]. Oriuchi N; Koizumi K; Koizumi M; Terui S; Yamaura H; Imai Y; Kaneta T; Nawano S; Kubo A; Nishimura T; Kinuya S; Tobinai K; Endo K Kaku Igaku; 2008 May; 45(2):99-113. PubMed ID: 19591405 [TBL] [Abstract][Full Text] [Related]
8. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209 [TBL] [Abstract][Full Text] [Related]
9. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Chiesa C; Botta F; Coliva A; Maccauro M; Devizzi L; Guidetti A; Carlo-Stella C; Seregni E; Gianni MA; Bombardieri E Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1745-57. PubMed ID: 19455328 [TBL] [Abstract][Full Text] [Related]
11. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315 [TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
13. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488 [TBL] [Abstract][Full Text] [Related]
14. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Wiseman GA; Gordon LI; Multani PS; Witzig TE; Spies S; Bartlett NL; Schilder RJ; Murray JL; Saleh M; Allen RS; Grillo-López AJ; White CA Blood; 2002 Jun; 99(12):4336-42. PubMed ID: 12036859 [TBL] [Abstract][Full Text] [Related]
15. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713 [TBL] [Abstract][Full Text] [Related]
16. Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma. Jacobs SA; Harrison AM; Swerdlow SH; Foon KA; Avril N; Vidnovic N; Joyce J; DeMonaco N; McCarty KS Mol Imaging Biol; 2009; 11(1):39-45. PubMed ID: 18773247 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Watanabe T; Terui S; Itoh K; Terauchi T; Igarashi T; Usubuchi N; Nakata M; Nawano S; Sekiguchi N; Kusumoto S; Tanimoto K; Kobayashi Y; Endo K; Seriu T; Hayashi M; Tobinai K Cancer Sci; 2005 Dec; 96(12):903-10. PubMed ID: 16367911 [TBL] [Abstract][Full Text] [Related]
18. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814 [TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Witzig TE Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375 [TBL] [Abstract][Full Text] [Related]
20. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. Conti PS; White C; Pieslor P; Molina A; Aussie J; Foster P J Nucl Med; 2005 Nov; 46(11):1812-8. PubMed ID: 16269594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]